The Summit
23rd - 25th July 2012
Summit Venue
Barton Creek Resort & Spa, Austin, Texas
The Next Generation Pharmaceutical Summit has grown to become the standard for senior level pharmaceutical executives looking to share ideas with peers, build partnerships with industry thought leaders, and hear from key experts on how to address some of their most pressing challenges in discovery and development, clinical research and beyond.
White Papers
TECAN: Label Free Cell Based Biosensors Bridging the Gap between Biosensors and Cell Based Assays
As the cost and risk involved in developing new pharmaceuticals continue to increase and tougher regulatory requirements are put in place, the need for technologies that accelerate the process of drug discovery becomes more urgent. In this article, we describe four instances of the use of Attana biosensors to obtain data that increases our understanding of molecular interactions and enhances our ability to select drug candidates based on physiologically relevant information. A TECAN Whitepaper
Comparison of the BD™ P800 and BD™ P700 Blood Collection Systems, BD Vacutainer® K2EDTA tube, and other Protease Inhibitors for the Preservation of Ac
Blood from 4 individual subjects was drawn into P700, P800, and K2EDTA BD evacuated blood collection tubes. Immediately after collection, Linco™ DPP-IV inhibitor or aprotinin was added to designated K2EDTA tubes from each subject. The tubes were immediately centrifuged and the plasma pooled from each tube/inhibitor type collected. An equivalent volume of plasma from each tube/inhibitor type (P700, P800, K2EDTA, K2EDTA+Linco™ DPP-IV inhibitor, and K2EDTA+aprotinin) was spiked within 1 hour of collection with 800 pM of Active GLP-1 (7-36 amide). Each set of plasma pools prepared from each subject was maintained at 25±3°C. Plasma aliquots were taken at 0, 2, 4, 6, 12, 24, 48 and 72 hours and stored frozen below -60°C until assayed for Active GLP-1 by ELISA.
Bioscan: Using In Vivo PET and SPECT Imaging to Accelerate Drug Discovery and Development
How non-invasive imaging with NanoSPECT/CT and NanoPET/CT can improve the efficiency of developing new diagnostics and therapies.
Agilent: An Introduction to High Throughput Microchromatography
The growing importance of biotherapeutics to the pharmaceutical industry has created an increasing demand for protein analysis techniques with high precision, high sensitivity, and high throughput. These techniques are used throughout the development process, starting with the discovery phase and continuing into lead optimization and characterization, preclinical and clinical trials (for both the biotherapeutic itself and related protein biomarkers), and manufacturing process development and control. Complex samples to be analyzed range from research samples from protein expression systems to biological samples such as serum to production cell lysates and cell culture supernatants. By Scott Fulton, BioSystem Development, Madison, WI USA
Immunospot: Monitoring of Cell Mediated Immunity
ELISPOT Assays Offer Unique Qualification for Cytokine-Based Immune Monitoring and Standardization Strategies – By Dr. Magdalena Tary-Lehmann, Cellular Technology Limited (CTL)
An Overview of Assay Quality Systems at Rules-Based Medicine®
Stringent guidelines of quality assurance and control (QA/QC) serve as the foundation for dependable and reproducible results in any analytical endeavor. To ensure the highest caliber data, Rules-Based Medicine (RBM) has established a rigorous set of criteria that serve as a guide through every stage of sample processing, from the development, validation, and manufacturing of our assays; to the testing, quality controlling and reporting of the data. Here we highlight step-by-step, the measures implemented by RBM that take Luminex xMAP® technology to a new level of reproducibility and ruggedness. The RBM platform combines the sensitivity and dynamic range of microsphere-based immuno-multiplexing with the precision and dependability of automated liquid handling. Together these features set RBM apart from other biomarker testing labs by offering high quality, cost-effective immunoassay measurements. A QA/QC White Paper by Brian T. Welsh, Ph.D. and Dr. James Mapes
An Integrated Approach for Clinical Trial Patient Retention
Recruiting the right patients in sufficient numbers to clinical trials is a well-recognized challenge. The growing and equally critical challenge is keeping them in the studies for their duration. A Whitepaper by Acurian
Leveraging On-Line Social Networks for Clinical Trial Patient Recruitment
The phenomenal growth and utilization of online social networks has created a range of new opportunities for recruiting patients into clinical trials. From Facebook to MySpace and Bebo to hi5, social networks offer sponsors a channel through which they can proactively and cost-effectively place trial information directly in front of potential participants. A Whitepaper by Acurian
Patient Data Security Paramount Issue in Clinical Trial Recruitment
The threats to patient data are increasing, and increasingly public. They typically do not come from some nefarious hackers, either. Rather, security breaches are usually the result of human error. A Whitepaper by Acurian
Crown Bioscience - Biology Expertise
Unlike any other CRO in the industry, Crown Bioscience was founded with the specific aim of building the resources needed to provide more clinically relevant data enabling Phase 0/Phase 1 studies in the preclinical stage of drug development.
Source: www.ngpsummit.com© 2012 GDS International Ltd. All rights reserved.
